myosin regulatory light chain interacting proteinGenealiases: IDOL · MIR
Q-omics provides the consensus-scored MYLIP profile across patient tissues and cancer cell-line models. MYLIP expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, MYLIP is differentially expressed in 11, with the highest sampling consensus in KICH. Additionally, MYLIP RNA expression shows 19,500 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight KIRC, KICH, and KIRP as cancer lineages where MYLIP shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MYLIP — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MYLIP survival associations across molecular data types. MYLIP RNA expression shows survival associations in the most cancer types (22), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MYLIP RNA expression–survival associations across cancer types. High MYLIP expression shows favorable associations in KIRC, LUAD, HNSC, LUSC, UCEC and BLCA. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for MYLIP RNA expression.
This table summarizes MYLIP tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for MYLIP. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MYLIP shows lower tumor expression in KICH, LUAD, KIRP and UCEC and higher tumor expression in LIHC and CHOL. The KICH box plot shows higher MYLIP RNA expression in normal versus tumor tissue (log2 FC = −1.468, t-test p < 0.001).
This table shows molecular features associated with MYLIP in patient tissues and cancer cell lines. In patient samples, MYLIP shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, MYLIP RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and SKIN.
